Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Experimental Cell Research(2015)
摘要
•Sorafenib reduces viability and ERK signaling in pHCC cells.•In vivo, sorafenib exerts a moderate tumor growth inhibition.•There was a significant reduction of vascularization.•Epithelial–mesenchymal transition is not involved in the resistance to sorafenib.•Inhibition of β-catenin signaling might enhance the effect of sorafenib in pHCC.
更多查看译文
关键词
pHCC,aHCC,ERK,HB
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要